We read with interest the article by Furnary and colleagues 1 showing that aprotinin does not increase the risk of renal failure in cardiac surgery patients, casting further doubt on the conclusions of a study by Mangano et al. 2 The article by Furnary et al demonstrates that risk for kidney failure is solely attributed to the greater numerical need for packed red blood cell transfusion in high-risk patients selected by physicians to receive aprotinin, and that packed red blood cells carry with them a highly significant independent risk of causing renal failure. These conclusions echo the concerns expressed in the aftermath of the article by Mangano et al, 3 that such an important confounding factor had not been corrected for in multivariate analysis.
